ESSA Pharma Inc (EPIX)

NASDAQ : Health Care
Prev Close 0.35
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.25 / 3.59
Avg Volume 133.40K
Exchange NASDAQ
Shares Outstanding 29.10M
Market Cap 10.77M
Div & Yield N.A. (N.A)

Latest News

Noble Capital Markets Initiates Research Coverage On ESSA Pharma Inc. (EPIX)

Noble Capital Markets, a leading small-cap focused investment firm, announces the initiation of research coverage of ESSA Pharma.

Mass. Biotech Firm Explores Strategic Alternatives

Struggling Mass. biotech firm Epix Pharmaceuticals explores strategic options, including sale

Epix Says It May File For Bankruptcy Protection

Epix Pharmaceuticals may file for bankruptcy protection; offers cash and stock for debt

Biotech Mailbag: Epix Pharmaceuticals

It may be best to wait for data from two clinical studies on Alzheimer's drug PRX-03140 before making any predictions about its prospects.

Thursday's Health Winners & Losers

EPIX plunges after ending development of its depression drug.

Wednesday's Health Winners & Losers

Stereotaxis' delayed catheter gets FDA approval.

Change Is the Only Constant

A wild day leaves major averages slightly higher. James Bianco opines on the credit crunch, and Dan Fitzpatrick on the search for Santa.

Tuesday's Winners & Losers: Earnings Can't Boost Goldman

Adobe rises on earnings; iRobot shares salute Army contract.

Tuesday's Health Winners & Losers

Epix Pharma climbs on study data.

Tuesday's Health Winners & Losers

OSI Pharma gains on an analyst upgrade.

Tuesday's Health Winners & Losers

HemoSense climbs on merger news.

Thursday's Health Winners & Losers

CryoCor soars on a positive recommendation from an FDA panel.

Monday's Late Winners & Losers

Yahoo! climbs on news of a CEO change.

Glaxo Continues Its Dealmaking

The British drug giant's deal with Genmab is its third in 11 days.

Tuesday's Health Winners & Losers

Valera takes off.

Epix, Glaxo in Development Deal

The companies pledge to develop drugs based on G-protein receptors.

Friday's Health Winners & Losers

Epix Pharmaceuticals sinks 15.6% on disappointing study results of its experimental anxiety drug.

Monday's Health Winners & Losers

Pozen jumps, but ImClone is lower.

Thursday's Health Winners & Losers

Nastech falls, while Biolase advances.

Health Stocks in Motion

Syneron is hammered on sales estimate.

Epix Swings the Ax

The company extends its interim chief's contract by two months.

Health Stocks in Motion

Alexion and Epix Pharmaceuticals fall after setbacks in the drug approval process.